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BACKGROUND
Both targeted decolonization and universal decolonization of patients in intensive 
care units (ICUs) are candidate strategies to prevent health care–associated infec-
tions, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA).
METHODS
We conducted a pragmatic, cluster-randomized trial. Hospitals were randomly as-
signed to one of three strategies, with all adult ICUs in a given hospital assigned to 
the same strategy. Group 1 implemented MRSA screening and isolation; group 2, 
targeted decolonization (i.e., screening, isolation, and decolonization of MRSA carri-
ers); and group 3, universal decolonization (i.e., no screening, and decolonization of 
all patients). Proportional-hazards models were used to assess differences in infec-
tion reductions across the study groups, with clustering according to hospital.
RESULTS
A total of 43 hospitals (including 74 ICUs and 74,256 patients during the interven-
tion period) underwent randomization. In the intervention period versus the base-
line period, modeled hazard ratios for MRSA clinical isolates were 0.92 for screen-
ing and isolation (crude rate, 3.2 vs. 3.4 isolates per 1000 days), 0.75 for targeted 
decolonization (3.2 vs. 4.3 isolates per 1000 days), and 0.63 for universal decoloni-
zation (2.1 vs. 3.4 isolates per 1000 days) (P = 0.01 for test of all groups being equal). 
In the intervention versus baseline periods, hazard ratios for bloodstream infection 
with any pathogen in the three groups were 0.99 (crude rate, 4.1 vs. 4.2 infections 
per 1000 days), 0.78 (3.7 vs. 4.8 infections per 1000 days), and 0.56 (3.6 vs. 6.1 infec-
tions per 1000 days), respectively (P<0.001 for test of all groups being equal). Univer-
sal decolonization resulted in a significantly greater reduction in the rate of all 
bloodstream infections than either targeted decolonization or screening and isola-
tion. One bloodstream infection was prevented per 99 patients who underwent de-
colonization. The reductions in rates of MRSA bloodstream infection were similar to 
those of all bloodstream infections, but the difference was not significant. Adverse 
events, which occurred in 7 patients, were mild and related to chlorhexidine.
CONCLUSIONS
In routine ICU practice, universal decolonization was more effective than targeted 
decolonization or screening and isolation in reducing rates of MRSA clinical iso-
lates and bloodstream infection from any pathogen. (Funded by the Agency for 
Healthcare Research and the Centers for Disease Control and Prevention; REDUCE 
MRSA ClinicalTrials.gov number, NCT00980980.)
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Health care–associated infection is a leading cause of preventable illness and death and often results from colo-
nizing bacteria that overcome body defenses.1-5 
Among the pathogens causing health care–associ-
ated infection, methicillin-resistant Staphylococcus 
aureus (MRSA) has been given priority as a target 
of reduction efforts because of its virulence and 
disease spectrum, multidrug-resistant profile, and 
increasing prevalence in health care settings, 
particularly among patients in the intensive care 
unit (ICU). Hospitals commonly screen patients 
in the ICU for nasal carriage of MRSA and use 
contact precautions with carriers.2-6 Nine states 
mandate such screening.7
Decolonization has been used to reduce trans-
mission and prevent disease in S. aureus carriers, 
primarily carriers of methicillin-resistant strains 
but also carriers of methicillin-sensitive ones.8,9 
S. aureus, including both methicillin-resistant and 
methicillin-susceptible strains, accounts for more 
health care–associated infections than any oth-
er pathogen.4 It is the most common cause of 
ventilator-associated pneumonia and surgical-site 
infection and the second most common cause of 
central-catheter–associated bloodstream infec-
tion.4 Decolonization commonly involves a multi-
day regimen of intranasal mupirocin and chlor-
hexidine bathing.
There is debate about whether decolonization 
should be used and, if so, whether to target high-
risk pathogens or patient populations that are 
susceptible to infection from many pathogens.10 
In particular, the broad antimicrobial activity of 
chlorhexidine makes it attractive for preventing 
health care–associated infection from many 
pathogens.11-14 Several studies have shown that 
daily chlorhexidine bathing of all patients in the 
ICU can reduce MRSA acquisition, the concen-
tration of bacteria on the body surface, and 
bloodstream infection from all pathogens.11-14 
A comparative-effectiveness trial is needed to 
determine what type of decolonization strategy 
works best to reduce MRSA and other pathogens 
in ICUs.15 In addition, it is important to know 
whether decolonization can be effective in routine 
ICU care. We conducted a cluster-randomized, 
pragmatic, comparative-effectiveness trial in adult 
ICUs to compare targeted and universal decolo-
nization with one another and with MRSA screen-
ing and contact precautions alone.
ME THODS
STUDY DESIGN
We designed the Randomized Evaluation of De-
colonization versus Universal Clearance to Elimi-
nate MRSA (REDUCE MRSA) trial, a three-group, 
cluster-randomized trial, to compare strategies 
for preventing MRSA clinical isolates and infec-
tions in adult ICUs in Hospital Corporation of 
America (HCA) hospitals. The trial design has 
been described previously,15 and the protocols are 
available with the full text of this article at NEJM 
.org. The training materials are provided in the 
Supplementary Appendix, available at NEJM.org. 
All the authors vouch for the accuracy of the re-
ported data and the fidelity of the study to the 
protocol. There was a 12-month baseline period 
from January 1 through December 31, 2009; a 
phase-in period from January 1 through April 7, 
2010; and an 18-month intervention period from 
April 8, 2010, through September 30, 2011.
The three strategy groups were defined as 
follows. In group 1 (screening and isolation), 
bilateral screening of the nares for MRSA was 
performed on ICU admission, and contact pre-
cautions were implemented for patients with a 
history of MRSA colonization or infection and 
for those who had any positive MRSA test. This 
was the previous standard of care in all hospitals. 
The MRSA screening program for patients in the 
ICU, who are a group at high risk for infection, 
began in 2007 at HCA hospitals.16 More than 
90% of the patients admitted to the ICU under-
went screening, and contact precautions were im-
plemented for carriers of MRSA and other multi-
drug-resistant pathogens.
In group 2 (targeted decolonization), MRSA 
screening and contact precautions were similar 
to those in group 1. Patients known to have 
MRSA colonization or infection underwent a 
5-day decolonization regimen consisting of twice-
daily intranasal mupirocin and daily bathing with 
chlorhexidine-impregnated cloths.
In group 3 (universal decolonization), there 
was no screening for MRSA on admission to the 
ICU. Contact precautions were similar to those 
in group 1. All patients received twice-daily intra-
nasal mupirocin for 5 days, plus daily bathing 
with chlorhexidine-impregnated cloths for the 
entire ICU stay.
All adult ICUs in a participating hospital were 
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assigned to the same study group. Contact-
precaution policies, which were based on long-
standing guidance from the Centers for Disease 
Control and Prevention (CDC), were identical and 
unchanged for all hospitals. Precautions were 
initiated on the basis of current or historical 
MRSA cultures or other standard indications.6 
Results of cultures obtained on admission be-
came available the next day.
STUDY OUTCOMES
The primary outcome was ICU-attributable, MRSA-
positive clinical cultures. Screening tests were 
excluded from all analyses because hospitals im-
plementing universal decolonization discontin-
ued such cultures. Secondary outcomes included 
ICU-attributable bloodstream infection caused by 
MRSA and ICU-attributable bloodstream infec-
tion caused by any pathogen. Clinical cultures 
were obtained at the clinician’s discretion.
RECRUITMENT AND ELIGIBILITY CRITERIA
Recruitment occurred among the 160 HCA hospi-
tals. Most were community hospitals with single-
occupancy ICU rooms. Eligibility criteria includ-
ed commitment by the hospital administration to 
have the hospital undergo randomization for the 
trial, less than 30% of patients in participating 
adult ICUs receiving either chlorhexidine bathing 
or intranasal mupirocin at baseline, stable use of 
infection-prevention initiatives and products dur-
ing the baseline period, and agreement to refrain 
from adopting new initiatives that would conflict 
with the trial. Throughout the study, corporate-
wide campaigns were used to ensure compliance 
with national practice guidelines.16-18
Each hospital obtained approval from an in-
stitutional review board, with more than 90% of 
the hospitals delegating review to the Harvard 
Pilgrim Health Care institutional review board. 
Patient notices about group-specific protocols 
were posted in each ICU room. The requirement 
for written informed consent was waived.19
RANDOMIZATION
Randomization was stratified to optimize bal-
ance in patient volume and baseline prevalence of 
MRSA carriage on the basis of clinical cultures 
and screening tests from July 2008 through June 
2009. Hospitals were ranked according to ICU 
volume and were grouped into sets of six. Within 
each set, we ordered the hospitals according to 
the prevalence of MRSA carriage in the ICU. Each 
group of three consecutive hospitals was random-
ly assigned, one to each strategy group, with the 
use of block randomization. Hospitals in states 
with legislative mandates for MRSA screening in 
the ICU were similarly and separately randomly 
assigned to group 1 or 2.
IMPLEMENTATION
On-site activities were implemented by hospital 
personnel responsible for quality-improvement 
initiatives, including ICU directors, infection pre-
ventionists, and nurse educators. Standard com-
munication channels were used, including group-
specific, computer-based training modules and 
daily electronic documentation by nursing staff 
for all groups. On-site training in bathing with 
chlorhexidine-impregnated cloths was provided 
to hospitals assigned to a decolonization regimen 
(i.e., group 2 or 3). Nursing directors performed 
at least three quarterly observations of bathing, 
including questioning staff about protocol details.
Investigators hosted group-specific coaching 
teleconferences at least monthly to discuss im-
plementation, compliance, and any new, poten-
tially conflicting initiatives. Compliance assess-
ment involved verification on 1 day per week for 
each ICU. HCA leadership evaluated trial pro-
cesses during routine hospital visits. Additional 
site visits were made at the request of the hospi-
tal or if compliance was found to be low.
Intranasal mupirocin ointment 2% (Bactro-
ban, GlaxoSmithKline) and 2% chlorhexidine–
impregnated cloths (Sage Products) were used 
for decolonization. All mupirocin and chlorhex-
idine-impregnated cloths were purchased at their 
usual cost by the participating hospitals. In groups 
2 and 3, bathing products and products used for 
wound prophylaxis that were incompatible with 
chlorhexidine were replaced with compatible 
products. Adverse events were managed by treat-
ing physicians.
DATA COLLECTION AND OUTCOME ASSIGNMENT
Census (i.e., the unit location of each patient for 
every hospitalization day), microbiologic, phar-
macy, supply-chain, nursing-query, and adminis-
trative data were obtained from corporate data 
warehouses, which undergo line-item validation 
until 99% accuracy is achieved. CDC criteria were 
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used for microbiologic outcomes (first outcome 
per patient). Pathogens were attributed to an ICU 
if the collection date occurred during the period 
from the third day after ICU admission through 
the second day after ICU discharge. For blood-
stream infections to be attributed to skin-com-
mensal organisms, the same organism had to be 
isolated from two or more blood cultures ob-
tained within 2 calendar days of one another.20
STATISTICAL ANALYSIS
We powered the trial on the basis of the rarest 
outcome, MRSA bloodstream infection. The study 
was designed to have 80% power to detect a 40% 
relative reduction in the rate of MRSA blood-
stream infection in group 2, and a 60% relative 
reduction in the rate in group 3, as compared 
with group 1. The primary analyses were con-
ducted according to the intention-to-treat prin-
ciple (as-assigned analyses) and were unadjusted. 
Proportional-hazards models with shared frail-
ties accounted for clustering within hospitals 
(see the Supplementary Appendix).21,22 The inter-
vention effect was assessed on the basis of the 
interaction between group and study period, re-
flecting the difference in hazard between the base-
line and intervention periods among the groups. 
Data from the phase-in period were excluded 
from all analyses. When the null hypothesis of 
equal changes across the groups was rejected, we 
examined pairwise comparisons.
Sensitivity analyses included multivariable 
covariate-adjusted models, as-treated models, 
models that excluded hospitals in states mandat-
ing MRSA screening in the ICU, models that 
accounted for assigned randomization strata, 
and models that excluded the small numbers of 
medical-only and surgical-only ICUs. Adjusted 
models accounted for age, sex, race, insurance 
type, coexisting conditions (defined with the use 
of codes from the International Classification of 
Diseases, 9th Revision), and surgery during the 
hospital stay. Analyses were performed with the 
use of SAS software, version 9.3 (SAS Institute).
R ESULT S
STUDY PARTICIPANTS
A total of 45 hospitals in 16 states underwent 
randomization (Fig. 1). A total of 43 (comprising 
74 ICUs) implemented the assigned intervention; 
2 hospitals that underwent randomization were 
excluded from all analyses because preexisting ex-
clusion criteria were discovered before the interven-
tion started. One hospital in group 2 (assigned to 
targeted decolonization) withdrew after the inter-
vention started and was included in the as-assigned 
analyses but not in the as-treated analyses.
Patient characteristics were similar across 
groups and between the baseline and interven-
tion periods (Table 1). There was excellent sepa-
ration of interventions across groups. In group 1, 
less than 1.0% of patients (range for hospitals in 
group, 0 to 2.1%) received mupirocin or chlorhex-
idine. In group 2, a total of 90.8% of MRSA 
carriers (range for hospitals in group, 56.5 to 
100%) received mupirocin and 88.8% (range for 
hospitals in group, 54.2 to 98.4%) received 
chlorhexidine. In group 3, a total of 86.1% of 
patients (range for hospitals in group, 41.0 to 
99.1%) received mupirocin and 80.8% (range for 
hospitals in group, 53.1 to 98.6%) received 
chlorhexidine.
Reasons for noncompliance included dis-
charge before scheduled bathing or mupirocin 
administration, discharge before MRSA-positive 
results were obtained, moribund state of the 
patient, length of ICU stay of less than 1 day, 
and patient’s decision to decline the intervention. 
MRSA screening occurred in 97.5% of patients 
(hospital range, 90.6 to 100%) in group 1, in 98.6% 
(hospital range, 95.6 to 100%) in group 2, and 
in 0.7% (hospital range, 0 to 4.7%) in group 3. Of 
the 69 proposed practice changes that occurred at 
various hospitals during the trial, 36 conflicted 
with the trial protocol and were not implemented.
OUTCOMES
For the primary outcome of ICU-attributable, 
MRSA-positive clinical cultures in the as-assigned 
analysis, the relative hazards differed signifi-
cantly among the groups in a comparison of the 
intervention period with the baseline period 
(P = 0.01) (Fig. 2). Pairwise analyses showed that 
universal decolonization resulted in a signifi-
cantly greater reduction in the hazard of MRSA-
positive clinical cultures than did screening and 
isolation (hazard ratio in group 3, 0.63; 95% con-
fidence interval [CI], 0.52 to 0.75; hazard ratio in 
group 1, 0.92; 95% CI, 0.77 to 1.10; P = 0.003 for 
test of all groups being equal).
The effects of the strategies on ICU-attribut-
able MRSA bloodstream infection were not sig-
nificantly different across the study groups 
(P = 0.11 for test of all groups being equal), al-
though the hazard reduction with universal de-
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colonization was greater than the reductions with 
the other strategies (hazard ratio, 0.72 [95% CI, 
0.48 to 1.08] vs. 1.23 [95% CI, 0.82 to 1.85] for 
screening and isolation and 1.23 [95% CI, 0.80 
to 1.90] for targeted decolonization). For ICU-
attributable bloodstream infection from any patho-
gen, differences among the groups were signifi-
cant (P<0.001 for test of all groups being equal). 
In pairwise comparisons, universal decolonization 
resulted in a significantly greater reduction in the 
hazard of infection (hazard ratio, 0.56; 95% CI, 
0.49 to 0.65) than either screening and isolation 
(hazard ratio, 0.99; 95% CI, 0.84 to 1.16; P<0.001) 
or targeted decolonization (hazard ratio, 0.78; 
95% CI, 0.66 to 0.91; P = 0.03). We found no sig-
nificant difference in mortality across the groups, 
although the trial was inadequately powered to 
observe even relatively large effects on death.
The effect of targeted decolonization was in-
termediate between the effects of usual care 
45 Hospitals (78 ICUs) underwent
randomization
55 Hospitals (98 ICUs) were assessed
for eligibility
10 Hospitals (20 ICUs) did
not meet eligibility criteria
States with mandatory MRSA screening
6 Hospitals (14 ICUs) randomly assigned
to group 1 or 2
Group 1
16 Hospitals (23 ICUs and
23,480 patients)
Group 3
13 Hospitals (29 ICUs and
26,024 patients)
States without mandatory MRSA screening
39 Hospitals (64 ICUs) randomly assigned
to group 1, 2, or 3
1 Hospital (3 ICUs) reported
meeting exclusion criteria
and was removed from trial
1 Hospital (1 ICU) reported
meeting exclusion criteria
and was removed from trial
5 Hospitals (11 ICUs) entered trial
13 Hospitals3 Hospitals
38 Hospitals (63 ICUs) entered trial
1 Hospital (2 ICUs) withdrew
from the study
Group 2
14 Hospitals (22 ICUs and
24,752 patients)
13 Hospitals (29 ICUs and
26,024 patients)
13 Hospitals (20 ICUs and
22,105 patients)
16 Hospitals (23 ICUs and
23,480 patients)





Figure 1. Recruitment, Randomization, and Inclusion in As-Assigned and As-Treated Analyses.
A total of 45 hospitals in 16 states were randomly assigned to a study group, with 43 (comprising 74 ICUs) beginning the assigned inter-
vention; 2 hospitals were excluded from all analyses because preexisting exclusion criteria were discovered before the intervention started. 
One hospital in group 2 (assigned to targeted decolonization) withdrew after the intervention started and was included in the as-assigned 
analyses but not the as-treated analyses. The numbers of patients shown in each group are the numbers from the intervention period.
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(i.e., screening and isolation) and universal de-
colonization for ICU-attributable MRSA cultures 
and bloodstream infection from any pathogen. 
Targeted decolonization resulted in significantly 
lower rates of bloodstream infection from any 
pathogen than did screening and isolation; other 
outcomes did not differ significantly between 
these two groups. Findings in all sensitivity 
analyses were similar to those in the as-assigned 
analysis (Table 2). 
Outcome events and their associated rates are 
shown in Table 3 and in the Supplementary Ap-
pendix. There were no significant between-group 
differences at baseline (P≥0.30 for all outcomes). 
The baseline rate of MRSA-positive clinical cul-
tures was higher in group 2 (4.3 per 1000 at-
tributable days) than in the other strategy groups 
(3.4 per 1000 attributable days in each), but the 
difference was not significant. At baseline, the 
rate of bloodstream infections from any patho-






Group 1 Group 2 Group 3 Group 1 Group 2 Group 3
Admission with ICU stay (no.) 15,816 15,218 17,356 23,480 24,752 26,024
Attributable ICU patient-days (no.) 63,135 57,418 69,668 88,222 92,978 101,603
ICU type (no.)†
Medical  3  5  5  3  5  5
Surgical  1  2  6  1  2  6
Mixed medical and surgical 19 14 18 19 15 17
Hospital stay (days)
Median  7  7  8  7  7  7
Interquartile range 5–12 5–12 5–12 5–12 5–12 5–12
ICU stay (days)
Median  3  3  3  3  3  3
Interquartile range 2–5 2–5 2–5 1–5 2–5 2–5
Age (yr)
Median 65 66 65 65 66 65
Interquartile range 52–77 53–77 51–77 52–77 53–77 52–77
Female sex (%)‡ 47.2 47.2 47.9 47.6 47.2 47.5
Nonwhite race (%)§ 25.9 22.1 30.8 25.9 23.5 31.7
Coexisting condition (%)
Diabetes 31.3 33.0 30.7 31.8 32.7 31.5
Renal failure 20.0 20.4 19.0 20.3 22.2 19.7
Cancer 10.4 10.8 14.1  9.9 10.8 13.0
Liver failure  3.4  4.4  3.9  4.0  4.1  4.2
History of MRSA infection (%)¶ 10.2 11.5 10.6  9.7 11.1  3.9
Surgery during hospitalization (%) 40.5 38.6 47.5 38.7 37.7 46.2
* Group 1 implemented methicillin-resistant Staphylococcus aureus (MRSA) screening and isolation; group 2, targeted 
 decolonization (i.e., screening, isolation, and decolonization of MRSA carriers with chlorhexidine and mupirocin); and 
group 3, universal decolonization (i.e., no screening and all patients underwent decolonization). At baseline, there were 
no significant between-group differences. For additional details, see the Supplementary Appendix.
† Differences in the number of ICUs in the groups between the baseline and intervention periods reflect the fact that one 
ICU in group 2 opened during the trial and one in group 3 closed.
‡ Data were missing for eight patients.
§ Race was determined from electronic administrative data at each hospital.
¶ A history of MRSA infection was identified with the use of all available screening and clinical cultures, with the history 
defined as MRSA carriage documented by the Hospital Corporation of America during the period from 1 year before 
admission to day 2 of the ICU stay. Data from group 3 during the intervention period are not comparable to data from 
the other groups because universal decolonization, without screening, was performed for all patients in this group. As 
the intervention progressed, patients who were readmitted to the ICU were less likely to be identified as MRSA-positive.
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gen was higher in group 3 (6.1 infections per 
1000 attributable days) than in groups 2 and 3 
(4.2 and 4.8 infections per 1000 attributable days, 
respectively), but the difference was not signifi-
cant (P = 0.87).
By chance, group 3 contained three of the 
four hospitals that performed bone marrow and 
solid-organ transplantations. These three hospi-
tals accounted for much of the excess risk in this 
group, including 72% of the baseline coagulase-
negative staphylococcal bloodstream infections 
(baseline risk of 0.01 events per patient in these 
three hospitals). The baseline risk per patient in 
all other hospitals in group 3 (0.004 events) was 
similar to the baseline risks in all hospitals in 
groups 1 and 2 (0.003 events in each group). 
During the intervention period, the risk declined 
in the three hospitals (0.002) and in all other 
hospitals implementing universal decolonization 
(0.0004), as compared with the baseline risks 
and as compared with the intervention risk for 
groups 1 and 2 (0.002 in each group). Analyses 
with adjustment for coexisting conditions such as 
cancer supported the findings of the as-assigned 
analyses (Table 2).
ADVERSE EVENTS
There were seven adverse events (two in group 2 
and five in group 3) (see the Supplementary Ap-
pendix). All involved mild pruritus or rash after 
chlorhexidine bathing and resolved on discon-
tinuation of the use of chlorhexidine-impregnat-
ed cloths.
DISCUSSION
Universal decolonization of patients in the ICU 
was the most effective strategy, significantly re-
ducing MRSA-positive clinical cultures by 37% and 
bloodstream infections from any pathogen by 44%. 
This effect was observed under usual practice 
conditions in a wide array of hospitals, including 
community hospitals, that had already implement-
ed national, evidence-based recommendations for 
preventing health care–associated MRSA infec-
tion. A total of 181 patients would need to un-
dergo decolonization to prevent one MRSA-posi-
tive clinical culture, and 99 patients would need 
to undergo decolonization to prevent one blood-
stream infection from any pathogen.
Several factors may account for our observa-
tion that universal decolonization had a greater 
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Figure 2. Effect of Trial Interventions on Outcomes.
Shown are group-specific hazard ratios and 95% confidence intervals (indi-
cated by vertical lines) for outcomes attributable to the intensive care unit. 
Results are based on unadjusted proportional-hazards models that account-
ed for clustering within hospitals. Analyses were based on the as-assigned 
status of hospitals. Panel A shows hazard ratios for clinical cultures that 
were positive for methicillin-resistant Staphylococcus aureus (MRSA) infec-
tion, Panel B hazard ratios for MRSA bloodstream infection, and Panel C 
hazard ratios for bloodstream infection from any pathogen. Bubble plots of 
hazard ratios (predicted random effects or exponentiated frailties) from in-
dividual hospitals relative to their group effects are shown. The size of the 
bubble indicates the relative number of patients contributing data to the trial.
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First, chlorhexidine reduces skin colonization by 
many pathogens, thus protecting patients in the 
ICU from their own microbiota during a period 
of heightened vulnerability to infection.11-14 Sec-
ond, universal decolonization reduces the environ-
mental microbial burden, reducing opportunities 
for patient-to-patient transmission.14,23 Third, 
universal decolonization began on the first ICU 
day, thus avoiding the delay in decolonization 
pending the results of screening tests.
Another potential benefit of universal decolo-
nization is the elimination of MRSA surveillance 
tests and the associated reduction in contact pre-
cautions, which can interfere with care.24 These 
findings have implications for legislative man-
dates requiring MRSA screening in the ICU.25 
Table 2. Hazard Ratios for Primary and Secondary Trial Outcomes.
Variable Hazard Ratio (95% CI)
Overall  
P Value




Unadjusted* 0.92 (0.77–1.10) 0.75 (0.63–0.89) 0.63 (0.52–0.75) 0.01
Adjusted 0.92 (0.77–1.10) 0.74 (0.62–0.88) 0.64 (0.53–0.77) 0.02
As-treated analysis, unadjusted 0.93 (0.78–1.11) 0.78 (0.65–0.94) 0.63 (0.52–0.75) 0.01
Randomization to all three groups, 
unadjusted analysis†
0.93 (0.76–1.13) 0.74 (0.62–0.89) 0.63 (0.52–0.75) 0.02
Randomization strata accounted for, 
unadjusted analysis
0.93 (0.78–1.11) 0.75 (0.63–0.89) 0.63 (0.52–0.75) 0.01
Mixed medical and surgical ICUs 
only, unadjusted analysis
0.93 (0.76–1.12) 0.71 (0.59–0.86) 0.57 (0.46–0.71)  0.004
Bloodstream infection
As-assigned analysis
Unadjusted 1.23 (0.82–1.85) 1.23 (0.80–1.90) 0.72 (0.48–1.08) 0.11
Adjusted 1.20 (0.80–1.81) 1.19 (0.77–1.84) 0.74 (0.49–1.12) 0.18
As-treated analysis, unadjusted 1.24 (0.82–1.86) 1.34 (0.84–2.15) 0.72 (0.48–1.08) 0.08
Randomization to all three groups, 
unadjusted analysis†
1.15 (0.74–1.79) 1.18 (0.74–1.89) 0.72 (0.48–1.08) 0.19
Randomization strata accounted for, 
unadjusted analysis
1.24 (0.83–1.86) 1.22 (0.79–1.88) 0.73 (0.48–1.09) 0.12
Mixed medical and surgical ICUs 
only, unadjusted analysis
1.15 (0.75–1.77) 1.20 (0.75–1.93) 0.72 (0.44–1.20) 0.28
Bloodstream infection from any pathogen
As-assigned analysis
Unadjusted‡ 0.99 (0.84–1.16) 0.78 (0.66–0.91) 0.56 (0.49–0.65) <0.001
Adjusted 0.98 (0.84–1.15) 0.77 (0.65–0.90) 0.55 (0.48–0.64) <0.001
As-treated analysis, unadjusted 0.99 (0.84–1.16) 0.78 (0.66–0.92) 0.56 (0.49–0.65) <0.001
Randomization to all three groups, 
unadjusted analysis†
0.93 (0.78–1.10) 0.77 (0.65–0.91) 0.56 (0.49–0.65) <0.001
Randomization strata accounted for, 
unadjusted analysis
0.99 (0.84–1.16) 0.78 (0.66–0.91) 0.56 (0.49–0.65) <0.001
Mixed medical and surgical ICUs 
only, unadjusted analysis
0.96 (0.81–1.13) 0.80 (0.67–0.96) 0.59 (0.50–0.69) <0.001
* P values in the pairwise analysis were as follows: P = 0.09 for the comparison of group 2 with group 1, P = 0.003 for the 
comparison of group 3 with group 1, and P = 0.16 for the comparison of group 3 with group 2.
† This analysis excluded the five hospitals in states with laws requiring MRSA screening in the ICU.
‡ P values in the pairwise analysis were as follows: P = 0.04 for the comparison of group 2 with group 1, P<0.001 for the 
comparison of group 3 with group 1, and P = 0.003 for the comparison of group 3 with group 2.
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Nevertheless, there may be occasions when 
screening is warranted, such as periodic monitor-
ing of resistance. Formal cost-effectiveness analy-
sis is needed to understand whether the observed 
cessation of screening, reduced contact precau-
tions, and reduced infections offset the product 
costs and the potential emergence of resistance. 
It remains to be seen whether universal decolo-
nization can obviate the need for all contact 
precautions for carriers of MRSA or other multi-
drug-resistant organisms.
The benefits attributable to universal decolo-
nization are notable for several reasons. First, 
the large reductions in infections that we ob-
served were achieved over and above the sub-
stantial reductions in bloodstream infections due 
to MRSA and other pathogens that have oc-
curred at HCA hospitals and other hospitals 
nationally within the past decade.3,26,27 Our 
study included a direct comparison with high-
compliance active surveillance and accompany-
ing contact precautions, which have been associ-
ated with decreased rates of MRSA transmission 
and MRSA bloodstream infection.9,16,25,27,28 Hos-
pitals that have not fully implemented a strategy 
of screening and isolation may derive additional 
benefit from this intervention. Second, universal 
decolonization was implemented as part of rou-
tine practice with the use of the usual infra-
structure of the hospital for practice change, 
without the need for on-site study personnel. 
These results are thus likely to be generally 
achievable as part of regular practice. Third, the 
intervention was effective in community hospi-
tals, which make up the majority of U.S. hospitals.
The reduction in bloodstream infections from 
any pathogen occurred in the context of the 
relatively higher baseline rates of infection for all 
pathogen types (gram-positive, gram-negative, 
and fungal) in group 3, as compared with the 
other groups. One explanation for these high 
rates is that this group included three of the four 
hospitals providing bone marrow and solid-
organ transplantations. Such differences across 
groups are largely accounted for by comparing 
the outcome rate in each hospital with that hos-
pital’s baseline rate, providing reassurance that 
the benefit is attributable to decolonization 
rather than to baseline variation in case mix or 
clinical practices across groups. In addition, 
group 3 did not have higher baseline rates of 
MRSA-positive clinical cultures than the other 
groups did, so regression to the mean would not 
explain the beneficial effect on that outcome.
It is unknown whether a threshold level of 
compliance with universal decolonization is re-
quired to achieve the observed benefit or wheth-
er a compliance rate higher than the rate in our 
study (85%) would yield further improvement. 
Although hospital staff members were aware of 
the assigned strategy, which could have resulted 
in unmeasured behavior that affected trial out-
comes,29 it is unclear what unmeasured behavior 
could effect a 44% improvement.
Table 3. Frequency and Rates of Outcomes during the Baseline and Intervention Periods, According to Study Group.*
Outcome Group 1 Group 2 Group 3
Baseline Intervention Baseline Intervention Baseline Intervention
no. of events (crude rate per 1000 patient-days)
MRSA clinical cultures 216 (3.4) 279 (3.2) 245 (4.3) 301 (3.2) 240 (3.4) 217 (2.1)
Bloodstream infection
MRSA 37 (0.6) 63 (0.7) 31 (0.5) 61 (0.6) 46 (0.6) 48 (0.5)
Any pathogen† 265 (4.2) 360 (4.1) 273 (4.8) 341 (3.7) 412 (6.1) 356 (3.6)
Gram-positive organism 165 (2.6) 228 (2.6) 159 (2.8) 203 (2.2) 253 (3.7) 187 (1.9)
Skin commensal organism 50 (0.8) 55 (0.6) 49 (0.9) 46 (0.5) 120 (1.8) 38 (0.4)
Noncommensal organism 115 (1.8) 173 (2.0) 110 (1.9) 157 (1.7) 133 (2.0) 149 (1.5)
Gram-negative organism 62 (1.0) 83 (0.9) 58 (1.0) 75 (0.8) 100 (1.5) 107 (1.1)
Candida species 38 (0.6) 49 (0.6) 56 (1.0) 63 (0.7) 59 (0.9) 62 (0.6)
* Provided rates are crude rates, defined as the number of events per 1000 ICU-attributable patient-days at risk for the event. Patient-days 
 after each event were excluded from the analysis; thus, denominators are different for each cell and are not included.
† The distribution of all bloodstream events is based on the first eligible event from any pathogen per patient. For example, a patient with a 
first ICU-associated bloodstream infection (due to a gram-positive organism) followed by a second ICU-associated bloodstream infection 
(due to a gram-negative organism) would be counted only in the listing for gram-positive organisms.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 24, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 368;24 nejm.org june 13, 20132264
This trial provides no information on the at-
tributable benefit of mupirocin, either alone or 
in combination with chlorhexidine. On the basis 
of microbiologic activity, any reduction in non–
S. aureus bloodstream infections should be at-
tributed to chlorhexidine. However, for S. aureus, 
the most common cause of health care–associ-
ated infection,4 clearance of the nasal reservoir 
in combination with body decolonization may be 
superior to either method alone.30
Widespread use of chlorhexidine and mupiro-
cin could possibly engender resistance.9,31,32 Mu-
pirocin resistance has been reported in some 
studies of MRSA decolonization,9,30 but not all 
such studies.8,32-35 MRSA resistance to chlorhex-
idine lacks a standard definition, but recent re-
ports suggest that resistant strains are rare in 
the United States.36,37 A gene encoding a multi-
drug efflux pump that is active against chlorhex-
idine has been reported in MRSA,38 but its clinical 
significance is not understood. Reduced suscep-
tibility to chlorhexidine has also been reported 
in gram-negative bacteria.39 It will therefore be 
important for surveillance programs to monitor 
mupirocin and chlorhexidine resistance.3,8
This trial was designed as a pragmatic, 
comparative-effectiveness trial implemented pri-
marily through usual hospital processes.15,19 We 
chose this design to obtain results that could be 
generalized to the broadest set of hospitals, to 
use processes potentially adoptable by many hos-
pitals, and to conduct a study of sufficient size 
— all ICUs in dozens of hospitals — with the 
available resources. Randomization of entire hos-
pitals allowed us to recruit a broad array of 
hospitals, including community hospitals with 
no prior experience in clinical research. Finally, 
the efficient design meant that the total cost of 
the trial, including the decolonizing product 
and contributed personnel effort, was less than 
$3 million, or approximately $40 per patient.
Opportunities to integrate comparative-effec-
tiveness research into routine clinical settings 
with the use of methods such as those used in 
the current study will increase as more hospitals 
adopt electronic health data systems and as multi-
center care-improvement collaboratives develop. 
This trial also highlights the importance of per-
forming rigorous evaluation of quality-improve-
ment initiatives and controlling the introduction 
of new processes and products. Harnessing such 
initiatives to identify best practices is an impor-
tant tenet of the advocacy by the Institute of 
Medicine for a learning health system.40
In conclusion, we found that universal decolo-
nization prevented infection, obviated the need 
for surveillance testing, and reduced contact iso-
lation. If this practice is widely implemented, 
vigilance for emerging resistance will be required.
The views expressed in this article are those of the authors 
and do not necessarily represent the views of the Agency for 
Healthcare Research and Quality (AHRQ), the Department of 
Health and Human Services, or the Centers for Disease Control 
and Prevention (CDC).
Supported by a contract with the AHRQ Healthcare-Associated 
Infections Program (HHSA290201000008I) and by a grant from the 
CDC Prevention Epicenters Program (1U01 CI000344, to Dr. Platt).
Dr. Septimus reports receiving consulting fees from 3M and 
lecture fees from Sage Products; Dr. Hayden, conducting research 
involving a contributed product from Sage Products; Dr. Wein-
stein, serving as an unpaid consultant for Sage Products; and Dr. 
Fraser, owning stock in Express Scripts. No other potential con-
flict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
References
1. Klevens RM, Edwards JR, Richards CL 
Jr, et al. Estimating health care-associated 
infections and deaths in U.S. hospitals, 
2002. Public Health Rep 2007;122:160-6.
2. Jarvis WR, Jarvis AA, Chinn RY. Na-
tional prevalence of methicillin-resistant 
Staphylococcus aureus in inpatients at US 
health care facilities, 2010. Am J Infect 
Control 2012;40:194-200.
3. Klevens RM, Morrison MA, Nadle J, 
et al. Invasive methicillin-resistant Staphy-
lococcus aureus infections in the United 
States. JAMA 2007;298:1763-71.
4. Sievert DM, Ricks P, Edwards JR, et al. 
Antimicrobial-resistant pathogens asso-
ciated with healthcare-associated infec-
tions: summary of data reported to the 
National Healthcare Safety Network at 
the Centers for Disease Control and Pre-
vention, 2009-2010. Infect Control Hosp 
Epidemiol 2013;34:1-14.
5. Huang SS, Hinrichsen VL, Datta R, 
et al. Methicillin-resistant Staphylococcus 
aureus infection and hospitalization in 
high-risk patients in the year following 
detection. PLoS One 2011;6(9):e24340.
6. Siegel JD, Rhinehart E, Jackson M, 
Chiarello L. 2007 Guideline for Isolation 
Precautions: preventing transmission of 
infectious agents in health care settings. 
Am J Infect Control 2007;35:Suppl 2:S65-
S164.
7. MRSA laws. Washington, DC: Asso-
ciation for Professionals in Infection Con-
trol and Epidemiology (http://www.apic 
.org/Resource_/TinyMceFileManager/ 
Advocacy-PDFs/MRSA_map.gif).
8. Ridenour G, Lampen R, Federspiel J, 
Kritchevsky S, Wong E, Climo M. Selec-
tive use of intranasal mupirocin and 
chlorhexidine bathing and the incidence of 
methicillin-resistant Staphylococcus aureus 
colonization and infection among inten-
sive care unit patients. Infect Control 
Hosp Epidemiol 2007;28:1155-61.
9. Robicsek A, Beaumont JL, Thomson 
RB, Govindarajan G, Peterson LR. Topical 
therapy for methicillin-resistant Staphylo-
coccus aureus colonization: impact on infec-
tion risk. Infect Control Hosp Epidemiol 
2009;30:623-32.
10. Wenzel RP, Edmond MB. Infection 
control: the case for horizontal rather 
than vertical interventional programs. Int 
J Infect Dis 2010;14:Suppl 4:S3-S5.
11. Climo MW, Yokoe DS, Warren DK, 
et al. Effect of daily chlorhexidine bathing 
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 24, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Targeted vs. Universal Decolonization for ICU Infection
n engl j med 368;24 nejm.org june 13, 2013 2265
on hospital-acquired infection. N Engl J 
Med 2013;368:533-42.
12. Bleasdale SC, Trick WE, Gonzalez IM, 
Lyles RD, Hayden MK, Weinstein RA. Ef-
fectiveness of chlorhexidine bathing to 
reduce catheter-associated bloodstream 
infections in medical intensive care unit 
patients. Arch Intern Med 2007;167:2073-9.
13. Popovich KJ, Hota B, Hayes B, Wein-
stein RA, Hayden MK. Effectiveness of 
routine patient cleansing with chlorhexi-
dine gluconate for infection prevention in 
the medical intensive care unit. Infect 
Control Hosp Epidemiol 2009;30:959-63.
14. Climo MW, Sepkowitz KA, Zuccotti 
G, et al. The effect of daily bathing with 
chlorhexidine on the acquisition of methi-
cillin-resistant Staphylococcus aureus, vanco-
mycin-resistant Enterococcus, and health-
care-associated bloodstream infections: 
results of a quasi-experimental multicenter 
trial. Crit Care Med 2009;37:1858-65.
15. Platt R, Takvorian SU, Septimus E, 
et al. Cluster randomized trials in com-
parative effectiveness research: random-
izing hospitals to test methods for preven-
tion of healthcare-associated infections. 
Med Care 2010;48:Suppl:S52-S57.
16. Perlin JB, Hickok JD, Septimus EJ, 
Moody JA, Englebright JD, Bracken RM. 
A bundled approach to reduce methicil-
lin-resistant Staphylococcus aureus infections 
in a system of community hospitals. 
J Healthc Qual 2013;35:57-69.
17. Yokoe DS, Mermel LA, Anderson DJ, 
et al. A compendium of strategies to pre-
vent healthcare-associated infections in 
acute care hospitals. Infect Control Hosp 
Epidemiol 2008;29:Suppl 1:S12-S21.
18. Healthcare Infection Control Practices 
Advisory Committee (HICPAC) guidelines. 
Atlanta: Centers for Disease Control and 
Prevention (http://www.cdc.gov/hicpac/).
19. Solomon MZ, Bonham AC. Ethical 
oversight of learning health care systems. 
Hastings Cent Rep 2013;43:Suppl:S1-S44.
20. National Healthcare Safety Network. 
Patient safety component manual. Atlanta: 
Centers for Disease Control and Prevention 
(http://www.cdc.gov/nhsn/settings.html).
21. Hayes RH, Moulton LH. Cluster ran-
domized trials. New York: CRC Press, 
2009:207.
22. Ripatti S, Palmgren J. Estimation of 
multivariate frailty models using penal-
ized partial likelihood. Biometrics 2000; 
56:1016-22.
23. Vernon MO, Hayden MK, Trick WE, 
Hayes RA, Blom DW, Weinstein RA. 
Chlorhexidine gluconate to cleanse pa-
tients in a medical intensive care unit: the 
effectiveness of source control to reduce 
the bioburden of vancomycin-resistant 
enterococci. Arch Intern Med 2006;166: 
306-12.
24. Morgan DJ, Diekema DJ, Sepkowitz K, 
Perencevich EN. Adverse outcomes asso-
ciated with contact precautions: a review 
of the literature. Am J Infect Control 
2009;37:85-93.
25. Weber SG, Huang SS, Oriola S, et al. 
Legislative mandates for use of active sur-
veillance cultures to screen for methicil-
lin-resistant Staphylococcus aureus and van-
comycin-resistant enterococci: position 
statement from the Joint SHEA and APIC 
Task Force. Infect Control Hosp Epide-
miol 2007;28:249-60.
26. Vital signs: central line–associated 
blood stream infections — United States, 
2001, 2008, and 2009. MMWR Morb Mor-
tal Wkly Rep 2011;60:243-8.
27. Jain R, Kralovic SM, Evans ME, et al. 
Veterans Affairs initiative to prevent 
methicillin-resistant Staphylococcus aureus 
infections. N Engl J Med 2011;364:1419-
30.
28. Moody J, Septimus E, Hickok J et al. 
Infection prevention practices in adult in-
tensive care units in a large community 
hospital system after implementing strat-
egies to reduce healthcare-associated 
methicillin-resistant Staphylococcus aureus 
infections. Am J Infect Control 2013;41: 
126-30.
29. Nijssen S, Bonten MJ, Weinstein RA. 
Are active microbiological surveillance 
and subsequent isolation needed to pre-
vent the spread of methicillin-resistant 
Staphylococcus aureus? Clin Infect Dis 2005; 
40:405-9.
30. Harbarth S, Dharan S, Liassine N, 
Herrault P, Auckenthaler R, Pittet D. Ran-
domized, placebo-controlled, double-blind 
trial to evaluate the efficacy of mupirocin 
for eradicating carriage of methicillin-
resistant Staphylococcus aureus. Antimicrob 
Agents Chemother 1999;43:1412-6.
31. Upton A, Lang S, Heffernan H. Mupi-
rocin and Staphylococcus aureus: a recent 
paradigm of emerging antibiotic resis-
tance. J Antimicrob Chemother 2003;51: 
613-7.
32. Simor AE, Stuart TL, Louie L, et al. 
Mupirocin-resistant, methicillin-resistant 
Staphylococcus aureus strains in Canadian 
hospitals. Antimicrob Agents Chemother 
2007;51:3880-6.
33. Ellis MW, Griffith ME, Dooley DP, 
et al. Targeted intranasal mupirocin to 
prevent colonization and infection by 
community-associated methicillin-resis-
tant Staphylococcus aureus strains in soldiers: 
a cluster randomized controlled trial. 
Antimicrob Agents Chemother 2007;51: 
3591-8.
34. Jones JC, Rogers TJ, Brookmeyer P, 
et al. Mupirocin resistance in patients col-
onized with methicillin-resistant Staphylo-
coccus aureus in a surgical intensive care 
unit. Clin Infect Dis 2007;45:541-7.
35. Harbarth S, Liassine N, Dharan S, 
Herrault P, Auckenthaler R, Pittet D. Risk 
factors for persistent carriage of methicil-
lin-resistant Staphylococcus aureus. Clin In-
fect Dis 2000;31:1380-5.
36. Fritz SA, Hogan PG, Camins BC, et al. 
Mupirocin and chlorhexidine resistance 
in Staphylococcus aureus in patients with 
community-onset skin and soft tissue in-
fections. Antimicrob Agents Chemother 
2013;57:559-68.
37. McNeil JC, Hulten KG, Kaplan SL, Ma-
honey DH, Mason EO. Staphylococcus aureus 
infections in pediatric oncology patients: 
high rates of antimicrobial resistance, 
antiseptic tolerance and complications. 
Pediatr Infect Dis J 2013;32:124-8.
38. Batra R, Cooper VS, Whiteley C, Patel 
AK, Wyncoll D, Edgeworth JD. Efficacy and 
limitation of a chlorhexidine-based de-
colonization strategy in preventing trans-
mission of methicillin-resistant Staphylo-
coccus aureus in an intensive care unit. Clin 
Infect Dis 2010;50:210-7.
39. Stickler DJ. Susceptibility of antibiotic-
resistant Gram-negative bacteria to bio-
cides: a perspective from the study of 
catheter biofilms. J Appl Microbiol 2002; 
92:Suppl:163S-S70S.
40. The learning health system series. 
Washington, DC: National Academies Press 
(http://www.nap.edu/catalog.php?record_
id=13301).
Copyright © 2013 Massachusetts Medical Society.
receive immediate notification when an article  
is published online first
To be notified by e-mail when Journal articles  
are published Online First, sign up at NEJM.org.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 24, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
